Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

December 01, 2015 11:10 AM ET

Life Sciences Tools and Services

Company Overview of KineMed, Inc.

Company Overview

KineMed, Inc. develops and commercializes proprietary biomarker platform technology. The company focuses on applying its proprietary biomarker platform technology to drug development, prescription, and non-prescription medical diagnostics and the pairing of drugs with diagnostic biomarker tests. It plans to commercialize biomarkers in the areas of muscle biology, fibrotic diseases, neurodegenerative diseases, cardiometabolic diseases, skin care, and cancer. The company has an agreement with BioPharma Forest, Inc. to develop and commercialize synthetic Ghrelin. KineMed, Inc. was founded in 2001 and is based in Emeryville, California.

5980 Horton Street

Suite 470

Emeryville, CA 94608

United States

Founded in 2001

49 Employees





Key Executives for KineMed, Inc.

Co-Founder, Chairman and Chief Executive Officer
Age: 71
Co-Founder, Chairman of the Scientific Advisory Board, President, Chief Scientific Officer and Director
Age: 63
Chief Operating Officer
Age: 82
Chief Business Officer and Executive Vice President
Executive Vice President of Research & Development
Age: 44
Compensation as of Fiscal Year 2015.

KineMed, Inc. Key Developments

KineMed Announces License Agreement with BioPharma Forest to Develop Late-Stage Synthetic Ghrelin

KineMed, Inc. announced that it has entered into an agreement with BioPharma Forest, Inc. to develop and commercialize synthetic Ghrelin. Under the terms of the Agreement, KineMed will develop the late-stage appetite stimulating agent, synthetic Ghrelin, for indications associated with muscle wasting. KineMed will apply its platform technology to assess skeletal muscle protein synthesis and whole body muscle mass to provide key decision-making data in an initial Phase II trial in 2016. KineMed has knowledge and experience in the muscle wasting area and believes its expertise, combined with application of its dynamic proteomic biomarkers of muscle anabolism, enables KineMed to carry out rapid proof-of-concept trials with a high degree of confidence for early detection and predictive efficacy in treating muscle wasting.

KineMed, Inc. Presents at BIO-Europe 2015, Nov-04-2015 10:45 AM

KineMed, Inc. Presents at BIO-Europe 2015, Nov-04-2015 10:45 AM. Venue: Munich, Germany.

KineMed, Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 08:30 AM

KineMed, Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 08:30 AM. Venue: Parc 55 Hotel, San Francisco, California, United States.

Similar Private Companies By Industry

Company Name Region
BioDot, Inc. United States
Dormir Clinical Trials, Inc. United States
ChemDiv, Inc. United States
Global Pharma Analytics United States
Huxley Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Private Placement
June 11, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KineMed, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at